The PT-141 / Vyleesi Starter Guide

The evidence base in plain English

Vyleesi was approved by the FDA on June 21, 2019 for premenopausal women with acquired, generalized HSDD. The approval was based on the RECONNECT trials - two phase 3 randomized, double-blind, placebo-controlled studies (NCT02333071 and NCT02338960) that together enrolled 1,247 premenopausal women. About 25% of women on Vyleesi reached a meaningful improvement on the Female Sexual Function Index desire score, versus 17% on placebo (FDA Vyleesi Prescribing Information, 2019; PMID 31599840 - Kingsberg et al. 2019).

Honest framing: that is roughly an 8-percentage-point absolute benefit over placebo. It is real but modest. Vyleesi is not Viagra for women. It is a moderate-effect drug that helps roughly one in twelve women who would not have responded to placebo alone, on top of the placebo response itself.

Side effects from the trials: nausea was the most common at 40% of treated patients (1% on placebo). Hyperpigmentation (darkening of skin, gums, or face) occurred in about 1% of patients during 8-or-fewer doses per month and increased with more doses (PMID 31429064 - Dhillon and Keam 2019, Drugs).

Week 0: the doctor conversation

The right starting point is a women's health telehealth provider, an OB/GYN, or a sexual-medicine specialist. Vyleesi is FDA-approved and on the standard formulary - any qualified prescriber can write it.

Three questions for the appointment:

• Is HSDD the right diagnosis for what I am experiencing? The drug is approved for acquired, generalized HSDD specifically. If your low desire is situational (only with one partner, only in certain contexts) or explained by depression, an SSRI side effect, or relationship distress, Vyleesi is probably not the right answer. A good provider will rule those out before prescribing.
• Can you write a Vyleesi prescription, and which pharmacy stocks it? Vyleesi is delivered via a prefilled, disposable autoinjector pen (a single-use device that you press against your skin to deliver the dose, similar to an EpiPen but smaller). Not every pharmacy stocks it; ask which one will fill the script.
• Are there any blood pressure or cardiovascular concerns I should be screened for first? The drug raises blood pressure transiently. Patients with uncontrolled hypertension or known cardiovascular disease should not use it. A baseline blood pressure check is the standard pre-prescription step.

Week 1: branded Vyleesi vs compounded PT-141

This is the fork in the road that determines which guide you are following.

Branded Vyleesi (FDA-approved path). Single-use prefilled autoinjector containing 1.75mg bremelanotide in 0.3mL solution, taken at least 45 minutes before anticipated sexual activity, max one dose per 24 hours, max 8 doses per month. Cost typically $99 to $325 per autoinjector pen depending on insurance coverage and the manufacturer copay program. Several telehealth providers (Hims/Hers, women's-health-specific platforms) prescribe Vyleesi directly. This is the path with the trial data, the safety profile, and the FDA label behind it.

Compounded PT-141 (gray market). Research peptide vendors and some compounding pharmacies sell PT-141 powder for reconstitution and subcutaneous injection. Doses in this space typically run 1 to 2mg subQ as needed before sexual activity. This is where the conversation about men's libido, post-SSRI sexual dysfunction, and PFS (post-finasteride syndrome) lives, because none of those are FDA-approved indications. The drug is the same molecule, but the regulatory and quality framing is different.

If you are a premenopausal woman with diagnosable HSDD, branded Vyleesi is the right path. If you are exploring off-label use for libido in another context, do that with eyes open about which evidence base you are drawing from.

How to use Vyleesi - the FDA label

• 1.75mg subQ (subcutaneous - injected just under the skin) into the abdomen or thigh, via the prefilled autoinjector, at least 45 minutes before anticipated sexual activity (FDA label).
• Maximum one dose per 24 hours. Do not redose if it does not seem to work the first time.
• Maximum 8 doses per month. The hyperpigmentation risk increases with frequent use.
• Take an anti-nausea medication if needed. 40% of users experience nausea, especially on the first one or two doses. Many providers co-prescribe ondansetron (brand name Zofran) to take alongside the first few doses. Ask about it on the call.
• Avoid alcohol within 6 hours of dosing. The label recommends caution because of the transient blood pressure rise.
• Track results across at least 4 to 8 doses before deciding if it is working. The FDA label specifically advises stopping if no improvement is seen after 8 doses.

What success looks like

The RECONNECT trials measured success by improvement on the Female Sexual Function Index desire score and the Female Sexual Distress Scale - Desire/Arousal/Orgasm score. In practical terms: more interest in sex, less distress about the lack of interest, and at least some of the dosing instances producing a real subjective shift in arousal.

Roughly 25% of women on Vyleesi hit the responder threshold in trials. Roughly 17% on placebo did. That means about a third of the responders are responding to the drug specifically, and about two thirds are responding to the placebo effect of taking action. Both responses are real. But you should know going in that the drug is not a coin flip - it is a moderate-effect tool that works for some women and not for others.

If 8 doses produce no measurable benefit, stop and have the follow-up conversation. There may be a different underlying issue (depression, an SSRI side effect, relationship distress, hormonal cause) that needs addressing instead.

What to skip

• Daily Vyleesi dosing. The label is on-demand, not daily. Daily use was not studied and is not what the safety data covers.
• Combining Vyleesi with other libido protocols at the same time. If you start Vyleesi alongside a testosterone trial, an SSRI taper, and a relationship-therapy course in the same month, you cannot tell what is working. Add one variable at a time.
• Research-vendor "PT-141 nasal spray" with no compounding-pharmacy involvement. The FDA-approved route is subQ injection. Nasal-spray bremelanotide was studied earlier in development but failed FDA approval in that delivery format because of inconsistent dosing and the same blood pressure concerns.
• Vyleesi for postmenopausal women. The drug is not approved for that population. Different conversation, different evidence base, talk to your provider about local-estrogen and other appropriate options.

Subscribe to the dispatch

The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Broken down for normal humans.

Subscribe free